【摘要】 目的 观察托毗酯单药治疗成人和儿童各型癫癎的临床效果与安全性。方法 用开放性试验的方法对3４例癫癎患者进行了添加转单药以及首诊单药的托吡酯治疗；以加用托吡酯前３个月的月均发作频率为基准，与单用或转换单用托吡酯进入稳定期后３个月的月均发作频率进行比较，按常规计算发作减少百分比的中位值和有效率百分比。结果：托吡酯无论在添加转单药还是单药的治疗上均有明显疗效，且抗癎谱广，可用于单纯部分性发作有或全面性发作、复杂部分性发作有或全面性发作、婴儿痉挛症，无耐药现象。１４岁以上者托吡酯单药治疗的剂量明显低于添加治疗组。托吡酯的副反应以中枢神经系统最常见，但导致治疗中断的副反应尚未见到。结论 托吡酯是一个广谱抗癫■药，疗效肯定，无耐药性，无严重副反应，可用于单药治疗。更多还原

【Abstract】 Objective To assess the clinical efficacy and safety of topiramate in adult and children patients with epilepsy. Methods Open-la- bel experience with topiramate as add-on to monotherapy and monotherapy were analyzied. The efficacy was assessed by comparing the average frequen- cy per month of 3 months after topiramate added to maintenance period to the baseline therapy. Results Topiramate may prove to be a valuable new antiepileptic drug for both monotherapy and add-on to monotherapy in partial onset epilepsy, general onset epilepsy and West syndrome, and had not tolerance. The topiramate dosage in patients with monotherapy is lower than with add-on therapy significantly, and the most common adverse events were CNS-related, but no patients discontinued therapy. Conclusions The topiramate as monotherapy is good efficacy and widespread antiepileptic drug, and has not tolerance and severe adverse events.更多还原